Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Anne Fia Grann, Reimar Wernich Thomsen, Jacob Bonde Jacobsen, Mette Nørgaard, Jan Blaakær & Mette Søgaard. (2013) Comorbidity and survival of Danish ovarian cancer patients from 2000–2011: a population-based cohort study. Clinical Epidemiology 5:sup1, pages 57-63.
Read now
Read now
Articles from other publishers (12)
Miroslav Popović, Tanja Milić-Radić & Arnela Cerić-Banićević. (2021) The clinical and pathological characteristics and survival of patients with advanced ovarian cancer. Scripta Medica 52:3, pages 205-210.
Crossref
Crossref
M. Timmermans, N. Zwakman, G.S. Sonke, K.K. Van de Vijver, M.J. Duk, M.A. van der Aa & R.F. Kruitwagen. (2019) Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology 240, pages 364-369.
Crossref
Crossref
Saisai Li, Xiaoli Hu, Miaomiao Ye & Xueqiong Zhu. (2018) The prognostic values of the peroxiredoxins family in ovarian cancer. Bioscience Reports 38:5.
Crossref
Crossref
Lene Seibæk, Dorthe Hjort Jakobsen & Claus Høgdall. (2018) The Danish Gynecological Cancer Nursing Database: Creating Evidence for Quality Improvements in Preoperative and Postoperative Cancer Care. International Journal of Gynecologic Cancer 28:4, pages 802-807.
Crossref
Crossref
Indah Nur Damayanti, Indra Yulianti & Etty Hary Kusumastuti. (2018) Three years survival rate of epithelial ovarian cancer patients in Dr. Kariadi Hospital, Semarang, Central Java. Majalah Obstetri & Ginekologi 24:3, pages 100.
Crossref
Crossref
M. Timmermans, G.S. Sonke, K.K. Van de Vijver, M.A. van der Aa & R.F.P.M. Kruitwagen. (2018) No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. European Journal of Cancer 88, pages 31-37.
Crossref
Crossref
Shanyang He, Yalan Deng, Yanbin Liao, Xiaojin Li, Jun Liu & Shuzhong Yao. (2017) CREB5 promotes tumor cell invasion and correlates with poor prognosis in epithelial ovarian cancer. Oncology Letters.
Crossref
Crossref
Charlotte E. Joslin, Katherine C. Brewer, Faith G. Davis, Kent Hoskins, Caryn E. Peterson & Heather A. Pauls. (2014) The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago. Gynecologic Oncology 135:2, pages 285-291.
Crossref
Crossref
L. Lydiksen, S. Jensen-Fangel & J. Blaakaer. (2014) Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?. Gynecologic Oncology 133:3, pages 454-459.
Crossref
Crossref
Seung Hee Cho, Mi Hee Park, Hee Peom Lee, Myong Ki Back, Ha Chang Sung, Hee Won Chang, Joo Hwan Kim, Heon-Sang Jeong, Sang Bae Han & Jin Tae Hong. (2014) (E)-2,4-Bis(p-hydroxyphenyl)-2-butenal enhanced TRAIL-induced apoptosis in ovarian cancer cells through downregulation of NF-κB/STAT3 pathway. Archives of Pharmacal Research 37:5, pages 652-661.
Crossref
Crossref
Simona Ferraro & Mauro Panteghini. (2013) Is serum human epididymis protein 4 ready for prime time?. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 51:2, pages 128-136.
Crossref
Crossref
Lene Seibaek, Jan Blaakaer, Lone Kjeld Petersen & Lise Hounsgaard. (2012) Ovarian cancer surgery: health and coping during the perioperative period. Supportive Care in Cancer 21:2, pages 575-582.
Crossref
Crossref